Skip to main content
Clinical Trials/NCT00773201
NCT00773201
Completed
Phase 1

Identification of the Genetic Sources of Variability of the Adaptation of the Ventricular Repolarisation at a Pharmacological and Physiological Stimulus in an Apparently Normal Population

Assistance Publique - Hôpitaux de Paris1 site in 1 country997 target enrollmentFebruary 2008

Overview

Phase
Phase 1
Intervention
Sotalol 80 mg
Conditions
Healthy Volunteers
Sponsor
Assistance Publique - Hôpitaux de Paris
Enrollment
997
Locations
1
Primary Endpoint
The elongation of the corrected interval QT duration 3 hours after the unique oral taking of an 80 mg dose of Sotalol.
Status
Completed
Last Updated
13 years ago

Overview

Brief Summary

The main objective is to research for genetic factors involved in the extreme modifications of the QT interval of the electrocardiogram in answer to a pharmacological stimulation (sotalol) and physiological stimulation in the apparently normal general population.

The phenotypic characterization, based on the ventricular repolarisation dynamics will be used aiming at term of the predictive genetic factors of the acquired long QT syndrome

Detailed Description

Study of 1000 apparently healthy subjects which will receive an unique dose of Sotalol and will have an effort test on ergonomic bicycle, an auditive stimulation and a taking of DNA.

Registry
clinicaltrials.gov
Start Date
February 2008
End Date
March 2012
Last Updated
13 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Both sexes
  • Age between 18 and 60 years
  • European or North African Origin
  • Body mass index between 19 and 29 kg / m ²
  • Obtaining informed and written consent

Exclusion Criteria

  • Heart rate \< 50 bpm
  • Systolic blood pressure \< 100 mm Hg
  • Atrioventricular block
  • Known chronic illness with chronic treatment
  • Raynaud phenomenon
  • QT prolonging drug
  • Family or personal history of the congenital long QT syndrome
  • QT/QTc Fridericia (QTcf) \> 450 ms
  • Pregnancy

Arms & Interventions

1

Healthy subjects

Intervention: Sotalol 80 mg

Outcomes

Primary Outcomes

The elongation of the corrected interval QT duration 3 hours after the unique oral taking of an 80 mg dose of Sotalol.

Time Frame: 3 hours after the taking of Sotalol

Secondary Outcomes

  • Look for associations between these phenotypes of electrocardiographically answer and mutations or polymorphisms.(At the inclusion visit)
  • Constitute a biological base and a phenotypic base of resources which will allow to define answer phenotypes to the implemented dynamic tests(At the inclusion visit)

Study Sites (1)

Loading locations...

Similar Trials